LU91104I2 - Derive o-alkyle de la rapamycine et son utilisation, en pariculier comme immunosuppresseur. - Google Patents

Derive o-alkyle de la rapamycine et son utilisation, en pariculier comme immunosuppresseur.

Info

Publication number
LU91104I2
LU91104I2 LU91104C LU91104C LU91104I2 LU 91104 I2 LU91104 I2 LU 91104I2 LU 91104 C LU91104 C LU 91104C LU 91104 C LU91104 C LU 91104C LU 91104 I2 LU91104 I2 LU 91104I2
Authority
LU
Luxembourg
Prior art keywords
alkyl
rapamycin
immunosuppressant
allyl
alkyl derivative
Prior art date
Application number
LU91104C
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10723188&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU91104(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of LU91104I2 publication Critical patent/LU91104I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Dental Preparations (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
LU91104C 1992-10-09 2004-09-29 Derive o-alkyle de la rapamycine et son utilisation, en pariculier comme immunosuppresseur. LU91104I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929221220A GB9221220D0 (en) 1992-10-09 1992-10-09 Organic componds
PCT/EP1993/002604 WO1994009010A1 (fr) 1992-10-09 1993-09-24 Derives o-alkyles de la rapamycine et leur utilisation, en particulier comme immunosuppresseurs

Publications (1)

Publication Number Publication Date
LU91104I2 true LU91104I2 (fr) 2004-11-29

Family

ID=10723188

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91104C LU91104I2 (fr) 1992-10-09 2004-09-29 Derive o-alkyle de la rapamycine et son utilisation, en pariculier comme immunosuppresseur.

Country Status (28)

Country Link
US (2) US5665772A (fr)
EP (3) EP1413581A1 (fr)
JP (2) JP3117462B2 (fr)
KR (2) KR100308598B1 (fr)
AT (2) ATE272063T1 (fr)
AU (1) AU676198B2 (fr)
BR (1) BR1100353A (fr)
CA (2) CA2145383C (fr)
CY (2) CY2125B1 (fr)
CZ (1) CZ283333B6 (fr)
DE (3) DE122004000033I2 (fr)
DK (2) DK0867438T3 (fr)
ES (2) ES2124793T3 (fr)
FI (2) FI109540B (fr)
FR (1) FR04C0012I2 (fr)
GB (1) GB9221220D0 (fr)
GE (1) GEP20002331B (fr)
HU (1) HU224074B1 (fr)
LU (1) LU91104I2 (fr)
NL (1) NL300154I2 (fr)
NO (3) NO307053B1 (fr)
NZ (1) NZ256026A (fr)
PL (1) PL176174B1 (fr)
PT (1) PT867438E (fr)
RO (1) RO114451B1 (fr)
RU (1) RU2143434C1 (fr)
SK (2) SK285256B6 (fr)
WO (1) WO1994009010A1 (fr)

Families Citing this family (464)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA935110B (en) * 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
ZA935111B (en) * 1992-07-17 1994-02-04 Smithkline Beecham Corp Rapamycin derivatives
USRE40596E1 (en) * 1993-04-08 2008-12-02 Novartis Ag Rapamycin assay
GB9307491D0 (en) 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
DE69435044T2 (de) 1993-04-23 2008-09-18 Wyeth Rapamycin - Konjugate und Antikörper
US7279561B1 (en) * 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
USRE37421E1 (en) 1993-07-16 2001-10-23 Smithkline Beecham Corporation Rapamycin derivatives
SI1033128T2 (sl) * 1993-09-28 2012-02-29 Scherer Gmbh R P Izdelava mehke Ĺľelatinaste kapsule
WO1995014023A1 (fr) * 1993-11-19 1995-05-26 Abbott Laboratories Analogues semi-synthetiques de rapamycine (macrolides) utilises comme immunomodulateurs
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5912253A (en) * 1993-12-17 1999-06-15 Novartis Ag Rapamycin derivatives
GB9405350D0 (en) * 1994-03-18 1994-05-04 Sandoz Ltd Organic compounds
PE52896A1 (es) 1994-10-26 1996-12-12 Novartis Ag Composicion farmaceutica
US7205279B2 (en) * 1995-10-25 2007-04-17 Novartis Ag Pharmaceutical compositions
ATE299017T1 (de) * 1994-10-26 2005-07-15 Novartis Pharma Gmbh Arzneimittel
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
GB9618952D0 (en) * 1996-09-11 1996-10-23 Sandoz Ltd Process
US6187757B1 (en) 1995-06-07 2001-02-13 Ariad Pharmaceuticals, Inc. Regulation of biological events using novel compounds
EP0833828B1 (fr) * 1995-06-09 2002-11-20 Novartis AG Derives de rapamycine
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
KR100616020B1 (ko) * 1996-03-27 2007-01-31 노파르티스 아게 맥관장애및이종이식술에서의라파마이신유도체의용도
EP1208847B8 (fr) 1996-07-30 2007-02-14 Novartis AG Compositions pharmaceutiques destinees au traitement des etats de rejet de greffe ainsi que des maladies autoimmunes ou inflammatoires
CN1235608A (zh) * 1996-09-09 1999-11-17 美国家用产品公司 烷基化的雷帕霉素衍生物
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
US6220537B1 (en) 1997-03-07 2001-04-24 Daiwa Seiko, Inc. Fishing spinning reel having smoothly shaped rail portion
US6306166B1 (en) * 1997-08-13 2001-10-23 Scimed Life Systems, Inc. Loading and release of water-insoluble drugs
PL342742A1 (en) * 1998-03-06 2001-07-02 Novartis Ag Emulsion-type pre-concentrates containing cyclosporin or macrolyde
DK1064942T3 (da) * 1998-03-26 2004-11-01 Fujisawa Pharmaceutical Co Sustained release-fremstilling af et makrolid
US20050031611A1 (en) * 1998-05-08 2005-02-10 Beth Israel Deaconess Medical Center Transplant tolerance by costimulation blockade and T-cell activation-induced apoptosis
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
BR9913052A (pt) * 1998-08-17 2001-05-08 American Home Prod Rapamicinas fotocilizadas
GB9826882D0 (en) 1998-12-07 1999-01-27 Novartis Ag Organic compounds
US7276506B2 (en) * 1998-12-28 2007-10-02 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US6946465B2 (en) * 1999-02-02 2005-09-20 4 Aza Bioscience Nv Immunosuppressive effects of pteridine derivatives
US6318654B1 (en) 1999-03-07 2001-11-20 Daiwa Seiko, Inc. Spinning reel for fishing
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
JP2002544167A (ja) 1999-05-10 2002-12-24 ノバルティス アクチエンゲゼルシャフト 有機化合物
USD440626S1 (en) 1999-06-08 2001-04-17 Daiwa Seiko, Inc. Line slider for a spinning fishing reel
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
BR0013399A (pt) * 1999-08-18 2002-04-30 American Home Prod ésteres sdz-rad solúveis em água
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
AU783158B2 (en) 1999-08-24 2005-09-29 Ariad Pharmaceuticals, Inc. 28-epirapalogs
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US20070032853A1 (en) * 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US6277983B1 (en) 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
RU2264405C2 (ru) * 1999-12-06 2005-11-20 Новартис Аг 40-o-(2-гидрокси)этилрапамицин в кристаллической несольватированной форме, фармацевтическая композиция, содержащая такой макролид в качестве действующего вещества, и способ его получения
EP2298299A3 (fr) * 2000-01-14 2012-02-29 The Trustees Of The University Of Pennsylvania Dérivés de rapamycine o-méthylée pour la réduction et l'inhibition du syndrome lymphoprolifératif
GB0008785D0 (en) 2000-04-10 2000-05-31 Novartis Ag Organic compounds
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US6670355B2 (en) * 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
JP2004507465A (ja) 2000-08-11 2004-03-11 ワイス エストロゲン受容体陽性癌腫の治療方法
EP1319008B1 (fr) 2000-09-19 2008-10-15 Wyeth Esters de rapamycine hydrosolubles
US6399625B1 (en) * 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
AU9486901A (en) 2000-09-29 2002-04-08 Cordis Corp Coated medical devices
US6440991B1 (en) 2000-10-02 2002-08-27 Wyeth Ethers of 7-desmethlrapamycin
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
DE60137273D1 (de) 2000-10-20 2009-02-12 Eisai R&D Man Co Ltd Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
PL409579A1 (pl) 2001-02-19 2015-03-02 Novartis Ag Leczenie raka
AU2005201004A1 (en) * 2001-02-19 2005-03-24 Novartis Ag Cancer treatment
AU2011226833B9 (en) * 2001-02-19 2014-07-03 Novartis Ag Cancer treatment
AU2016206379B2 (en) * 2001-02-19 2017-09-14 Novartis Ag Cancer Treatment
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
TWI233359B (en) * 2001-04-06 2005-06-01 Wyeth Corp Pharmaceutical composition for treating neoplasm
US6613083B2 (en) 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
WO2003004098A1 (fr) 2001-07-06 2003-01-16 Sucampo Ag Composition pour administration directe comprenant un inhibiteur de l'interleukine 2 et un agent antimicrobien
JP4202250B2 (ja) 2001-07-25 2008-12-24 バイオマリン ファーマシューティカル インコーポレイテッド 血液脳関門輸送を調節するための組成物および方法
US6939376B2 (en) * 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
AU2002366028A1 (en) * 2001-11-21 2003-06-10 Sucampo Ag Use of fk506 and analogues for treating allergic diseases
JP4547911B2 (ja) 2002-02-01 2010-09-22 アリアド・ファーマシューティカルズ・インコーポレイテッド リン含有化合物およびその用途
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
PL372103A1 (en) 2002-05-16 2005-07-11 Novartis Ag Use of edg receptor binding agents in cancer
CA2492153C (fr) * 2002-07-16 2012-05-08 Biotica Technology Limited Production d'analogues de ligand fkbp polyketidiques
NZ537829A (en) 2002-07-30 2006-09-29 Wyeth Corp Parenteral formulations containing a rapamycin hydroxyester
US8163726B2 (en) * 2002-09-18 2012-04-24 University Of Pennsylvania Method of inhibiting choroidal neovascularization
KR20080103117A (ko) 2002-09-24 2008-11-26 노파르티스 아게 탈수초성 장애의 치료에 있어서의 스핑고신-1-포스페이트 수용체 아고니스트
WO2004060283A2 (fr) 2002-12-16 2004-07-22 Nitromed, Inc. Composes a base de rapamycine nitrosee et nitrosylee, compositions et procedes d'utilisation
EP2181704B1 (fr) 2002-12-30 2015-05-06 Angiotech International Ag Liberation de médicaments a partir d'une composition polymère à gélification rapide
AR042938A1 (es) * 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
US20090093875A1 (en) 2007-05-01 2009-04-09 Abbott Laboratories Drug eluting stents with prolonged local elution profiles with high local concentrations and low systemic concentrations
AR043504A1 (es) * 2003-03-17 2005-08-03 Novartis Ag Composiciones farmaceuticas que comprenden rapamicina para el tratamiento de enfermedades inflamatorias
GB0307867D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20070155771A1 (en) * 2003-04-11 2007-07-05 David Rubinsztein Methods and means for treating protein conformational disorders
ATE352301T1 (de) * 2003-04-22 2007-02-15 Wyeth Corp Antineoplastische zusammensetzungen
RU2233285C1 (ru) * 2003-05-15 2004-07-27 Институт молекулярной генетики РАН Высокомеченный тритием [3h]-рапамицин
US7160867B2 (en) * 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
AU2004255340B2 (en) * 2003-07-08 2008-05-01 Novartis Ag Use of rapamycin and rapamycin derivatives for the treatment of bone loss
WO2005025574A2 (fr) * 2003-09-12 2005-03-24 4 Aza Bioscience Nv Derives de pteridine pour le traitement du choc septique et de maladies liees au tnf-$g(a)
CA2539324A1 (fr) 2003-09-18 2005-03-31 Macusight, Inc. Administration transsclerale d'agents therapeutiques
US20070032477A1 (en) * 2003-10-17 2007-02-08 Waer Mark J A Pteridine derivatives useful for making pharmaceutical compositions
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
GB0327840D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
EP1571151B1 (fr) * 2004-03-01 2008-12-24 Terumo Kabushiki Kaisha Procédé de préparation des dérives de rapamycine O-alkylés
ES2425167T3 (es) 2004-03-10 2013-10-11 Seradyn, Inc. Inmunoensayos para everolimús
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
US8551512B2 (en) * 2004-03-22 2013-10-08 Advanced Cardiovascular Systems, Inc. Polyethylene glycol/poly(butylene terephthalate) copolymer coated devices including EVEROLIMUS
US8778014B1 (en) 2004-03-31 2014-07-15 Advanced Cardiovascular Systems, Inc. Coatings for preventing balloon damage to polymer coated stents
AU2005238432A1 (en) * 2004-04-14 2005-11-10 Wyeth Process for preparing rapamycin 42-esters and FK-506 32-esters with dicarboxylic acid, precursors for rapamycin conjugates and antibodies
CA2562164A1 (fr) * 2004-04-27 2005-11-10 Wyeth Marquage de rapamycine au moyen de methylases specifiques de la rapamycine
WO2006115509A2 (fr) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Immuno-potentialisateurs a petites molecules et analyses visant a detecter leur presence
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
GB0417852D0 (en) 2004-08-11 2004-09-15 Biotica Tech Ltd Production of polyketides and other natural products
ATE483716T1 (de) 2004-08-27 2010-10-15 Cordis Corp Lösungsmittelfreies amorphes rapamycin
AU2005283422C1 (en) 2004-09-17 2017-02-02 Eisai R & D Management Co., Ltd. Medicinal composition
US7901451B2 (en) 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
BRPI0516308A2 (pt) * 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
KR20070070184A (ko) * 2004-10-28 2007-07-03 와이어쓰 자궁근종의 치료에 있어서 ｍＴＯＲ 억제제의 용도
US8021849B2 (en) * 2004-11-05 2011-09-20 Siemens Healthcare Diagnostics Inc. Methods and kits for the determination of sirolimus in a sample
WO2006053754A1 (fr) * 2004-11-19 2006-05-26 Novartis Ag COMBINAISONS DE PEPTIDES ANTI-ATHEROSCLEREUX ET D’UN AGENT INHIBANT LA mTOR ET PROCEDES POUR LES UTILISER
WO2006071966A2 (fr) * 2004-12-29 2006-07-06 The Brigham And Women's Hospital, Inc. Composes de rapamycine traitant la neurofibromatose de type 1
JP4974903B2 (ja) 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
GB0503936D0 (en) 2005-02-25 2005-04-06 San Raffaele Centro Fond Method
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
US7241771B2 (en) 2005-03-07 2007-07-10 Wyeth Oxepane isomer of 42-O-(2-hydroxy)ethyl-rapamycin
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
EP1896018A2 (fr) 2005-03-11 2008-03-12 Biotica Technology Limited Utilisations medicales de 39-demethoxy-rapamicyne et ses analogues
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
US7189582B2 (en) * 2005-04-27 2007-03-13 Dade Behring Inc. Compositions and methods for detection of sirolimus
EP2671507A3 (fr) 2005-04-28 2014-02-19 Proteus Digital Health, Inc. Système pharma-informatique
BRPI0611021A2 (pt) * 2005-05-31 2010-08-10 Novartis Ag combinação de inibidores de hmg-coa redutase e inibidores de mtor
US20070004767A1 (en) * 2005-06-30 2007-01-04 Gutmann David H Methods for treating neurofibromatosis 1
WO2007011707A2 (fr) 2005-07-15 2007-01-25 Micell Technologies, Inc. Enrobages polymeres renfermant de la poudre de medicament a morphologie commandee
WO2007011708A2 (fr) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent a revetement polymere renfermant de la rapamycine amorphe
WO2007010012A2 (fr) 2005-07-20 2007-01-25 Novartis Ag Combinaison de composes organiques
HRP20140338T1 (hr) 2005-07-25 2014-06-20 Emergent Product Development Seattle, Llc Smanjenje broja b-stanica upotrebom molekula koje se specifiäśno vežu na cd37 i cd20
WO2007015578A1 (fr) 2005-08-02 2007-02-08 Eisai R & D Management Co., Ltd. Procédé d’analyse de l’effet d’un inhibiteur de vascularisation
JP5164167B2 (ja) 2005-08-30 2013-03-13 ユニバーシティー オブ マイアミ 免疫調節性腫瘍壊死因子受容体２５（ｔｎｆｒ２５）のアゴニスト、アンタゴニスト及び免疫毒素
EP1776970A1 (fr) 2005-10-12 2007-04-25 Albert Schömig Implant avec revêtement multiple
JP2009514870A (ja) 2005-11-04 2009-04-09 ワイス ｍＴＯＲインヒビター、ハーセプチン、および／またはＨＫＩ−２７２の抗悪性腫瘍性組み合わせ
GB0523659D0 (en) * 2005-11-21 2005-12-28 Novartis Ag Organic compounds
RU2008121713A (ru) * 2005-12-20 2010-01-27 Вайет (Us) Контроль стабильности лекарственной формы cci-779 посредством контроля примесей лекарственныхого вещества
AU2007204410A1 (en) * 2006-01-12 2007-07-19 Novartis Ag Combination of mTOR inhibitor and antipolate compound
US20070173923A1 (en) * 2006-01-20 2007-07-26 Savage Douglas R Drug reservoir stent
GB0601406D0 (en) * 2006-01-24 2006-03-08 Novartis Ag Organic Compounds
LT1983984T (lt) * 2006-02-02 2018-06-11 Novartis Ag Tuberozinės sklerozės gydymas
WO2007092620A2 (fr) 2006-02-09 2007-08-16 Macusight, Inc. Formulations stables et leurs procedes de preparation et d'utilisation
US7622477B2 (en) * 2006-02-28 2009-11-24 Cordis Corporation Isomers and 42-epimers of rapamycin alkyl ether analogs, methods of making and using the same
US7678901B2 (en) * 2006-02-28 2010-03-16 Wyeth Rapamycin analogs containing an antioxidant moiety
MX2008011458A (es) * 2006-03-07 2008-09-24 Wyeth Corp Procedimiento para preparar conjugados de polietilenglicol solubles en agua de inmunosupresores de macrolidos.
PL2001466T3 (pl) 2006-03-23 2016-06-30 Santen Pharmaceutical Co Ltd Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
CA2996768C (fr) 2006-04-26 2020-12-08 Micell Technologies, Inc. Revetements contenant plusieurs medicaments
RU2448708C3 (ru) 2006-05-18 2017-09-28 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое средство против рака щитовидной железы
GB0609963D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
GB0609962D0 (en) * 2006-05-19 2006-06-28 Biotica Tech Ltd Novel compounds
CA2656112A1 (fr) * 2006-06-30 2008-05-08 Hanje Chen Polymeres biosensibles
WO2008009079A2 (fr) * 2006-07-20 2008-01-24 Gilead Sciences, Inc. Ptéridines substituées utilisables pour le traitement et la prévention des infections virales
US9259426B2 (en) 2006-07-20 2016-02-16 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US20100266590A1 (en) * 2006-08-02 2010-10-21 Demetri George D Combination therapy
CN101511793B (zh) 2006-08-28 2011-08-03 卫材R&D管理有限公司 针对未分化型胃癌的抗肿瘤剂
US20080051691A1 (en) * 2006-08-28 2008-02-28 Wyeth Implantable shunt or catheter enabling gradual delivery of therapeutic agents
US10695327B2 (en) 2006-09-13 2020-06-30 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US8088789B2 (en) 2006-09-13 2012-01-03 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
EP2083834B1 (fr) 2006-09-13 2017-06-21 Elixir Medical Corporation Composés de lactone macrocyclique et leurs procédés d'utilisation
MX2009002893A (es) 2006-09-18 2009-07-10 Raptor Pharmaceutical Inc Tratamiento de trastornos hepaticos mediante la administracion de conjugados de la proteina asociada al receptor (rap).
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
WO2008065887A1 (fr) 2006-11-27 2008-06-05 Terumo Kabushiki Kaisha Procédé de fabrication d'un dérivé de rapamycine o-alkylé, et dérivé de rapamycine o-alkylée
CA2679712C (fr) 2007-01-08 2016-11-15 Micell Technologies, Inc. Stents comportant des couches biodegradables
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
CA2673991C (fr) 2007-01-21 2012-02-07 Hemoteq Ag Procedes d'enrobage de ballonnets de catheters avec une quantite definie d'un agent actif
CN101600694A (zh) 2007-01-29 2009-12-09 卫材R&D管理有限公司 未分化型胃癌治疗用组合物
TW200845960A (en) * 2007-04-05 2008-12-01 Wyeth Corp Wortmannin-rapalog conjugate and uses thereof
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US9192697B2 (en) 2007-07-03 2015-11-24 Hemoteq Ag Balloon catheter for treating stenosis of body passages and for preventing threatening restenosis
CA2701186C (fr) 2007-10-05 2017-09-19 Evonik Canada Inc. Polymeres reticules oligofluores et leurs utilisations
WO2009049426A1 (fr) 2007-10-19 2009-04-23 Interface Biologics Inc. Revêtements autodégradables
KR101513326B1 (ko) 2007-11-09 2015-04-17 에자이 알앤드디 매니지먼트 가부시키가이샤 혈관 신생 저해 물질과 항종양성 백금 착물의 병용
CA2705764C (fr) 2007-11-14 2016-08-02 Biosensors International Group, Ltd. Procede et appareil de revetement d'endoprothese automatise
WO2009089549A1 (fr) 2008-01-11 2009-07-16 Massachusetts Eye & Ear Infirmary Animaux transgéniques de caspase dimérisable d'arrêt conditionnel
CN102215682A (zh) * 2008-03-11 2011-10-12 万能医药公司 大环内酯化合物及它们的使用方法
US20100048524A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
EP2278966B1 (fr) 2008-03-21 2019-10-09 The University of Chicago Traitement avec des antagonistes des opioïdes et des inhibiteurs mtor
EP2365003A1 (fr) 2008-04-11 2011-09-14 Emergent Product Development Seattle, LLC Produits d'immunothérapie de CD37 et combinaison avec un produit chimiothérapique bifonctionnel de celui-ci
US20110098241A1 (en) * 2008-04-14 2011-04-28 Poniard Pharmaceuticals, Inc. Rapamycin analogs as anti-cancer agents
SG192523A1 (en) 2008-04-17 2013-08-30 Micell Technologies Inc Stents having bioabsorbable layers
KR20110020928A (ko) 2008-06-20 2011-03-03 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
US8765162B2 (en) 2008-06-30 2014-07-01 Abbott Cardiovascular Systems Inc. Poly(amide) and poly(ester-amide) polymers and drug delivery particles and coatings containing same
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
EP2313122B1 (fr) 2008-07-17 2019-03-06 Micell Technologies, Inc. Dispositif médical d administration de médicament
US8092822B2 (en) 2008-09-29 2012-01-10 Abbott Cardiovascular Systems Inc. Coatings including dexamethasone derivatives and analogs and olimus drugs
EP2352459A4 (fr) * 2008-10-03 2013-09-25 Elixir Medical Corp Composés lactones macrocycliques et leurs méthodes d'utilisation
KR20110071014A (ko) 2008-10-17 2011-06-27 위스콘신 얼럼나이 리서어치 화운데이션 생물학적으로 활성인 알파-베타 펩티드의 제조 방법
EP2365802B1 (fr) 2008-11-11 2017-08-02 The Board of Regents,The University of Texas System Microcapsules de rapamycine et l'usage pour le traitement du cancer
PT2376088T (pt) 2008-12-23 2017-05-02 Gilead Pharmasset Llc Fosforamidatos de nucleósidos de 2-amino-purina 6-osubstituída
SG194404A1 (en) 2008-12-23 2013-11-29 Gilead Pharmasset Llc Synthesis of purine nucleosides
KR20110098849A (ko) 2008-12-23 2011-09-01 파마셋 인코포레이티드 뉴클레오시드 유사체
EP2380006A4 (fr) * 2009-01-21 2012-05-16 Biocon Ltd Procédé de détermination de la stabilité du sirolimus et procédé de préparation de sa forme stable
WO2010091306A1 (fr) 2009-02-05 2010-08-12 Tokai Pharmaceuticals Nouveaux promédicaments à base d'inhibiteurs cyp17 stéroïdiens/anti-androgènes
ES2665277T3 (es) 2009-03-13 2018-04-25 Katholieke Universiteit Leuven K.U. Leuven R&D Análogos de purina y su uso como agentes inmunosupresores
WO2010120552A2 (fr) 2009-04-01 2010-10-21 Micell Technologies, Inc. Endoprothèses enduites
CN102481361B (zh) 2009-04-16 2014-10-22 默沙东公司 用于治疗癌症的组合物和方法
WO2010121187A2 (fr) 2009-04-17 2010-10-21 Micell Techologies, Inc. Endoprothèses vasculaires ayant une élution contrôlée
IL255113B (en) 2009-05-06 2022-09-01 Laboratory Skin Care Inc Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
ES2550634T3 (es) 2009-07-10 2015-11-11 Boston Scientific Scimed, Inc. Uso de nanocristales para un balón de suministro de fármaco
EP2453938B1 (fr) 2009-07-17 2015-08-19 Boston Scientific Scimed, Inc. Nucléation de ballons d administration de médicament pour fournir une taille et une densité des cristaux améliorées
JP2013501057A (ja) 2009-08-03 2013-01-10 ユニバーシティー・オブ・マイアミ 制御性ｔ細胞のｉｎｖｉｖｏにおける増殖
DK2468281T3 (en) 2009-08-19 2016-03-21 Eisai R&D Man Co Ltd Quinolinderivatholdig pharmaceutical composition
MX2012004780A (es) 2009-10-23 2012-08-23 Lilly Co Eli Inhibidores de akt.
CA2777128A1 (fr) 2009-10-30 2011-05-05 Ariad Pharmaceuticals, Inc. Procedes et compositions pour le traitement du cancer
US9283211B1 (en) 2009-11-11 2016-03-15 Rapamycin Holdings, Llc Oral rapamycin preparation and use for stomatitis
US20170079962A1 (en) 2009-11-11 2017-03-23 Rapamycin Holdings, Llc Oral Rapamycin Preparation and Use for Stomatitus
CA2781210A1 (fr) 2009-11-18 2011-05-26 Novartis Ag Procedes et compositions pour traiter des tumeurs solides et d'autres malignites
WO2011072398A1 (fr) 2009-12-18 2011-06-23 Interface Biologics, Inc. Administration locale de médicaments à partir de revêtements auto-assemblés
CN102127092B (zh) * 2010-01-18 2013-04-17 东南大学 依维莫斯的制备
US11369498B2 (en) 2010-02-02 2022-06-28 MT Acquisition Holdings LLC Stent and stent delivery system with improved deliverability
JP2013521002A (ja) 2010-03-05 2013-06-10 プレジデント アンド フェロウズ オブ ハーバード カレッジ 誘導樹状細胞組成物及びその使用
PT2609923T (pt) 2010-03-31 2017-08-30 Gilead Pharmasset Llc Processo para a cristalização de 2-(((s)- (perfluorofenoxi)(fenoxi)fosforil)amino)propanoato de (s)-isopropilo
WO2011130232A1 (fr) 2010-04-13 2011-10-20 Novartis Ag Combinaison comprenant un inhibiteur de kinases 4 cyclines-dépendantes ou de kinases 6 cyclines-dépendantes (cdk4/6) et un inhibiteur de mtor pour le traitement du cancer
NZ602807A (en) 2010-04-16 2014-02-28 Novartis Ag 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one and an mtor inhibitor
CA2797110C (fr) 2010-04-22 2020-07-21 Micell Technologies, Inc. Endoprotheses et autres dispositifs ayant un revetement de matrice extracellulaire
EP2563391B1 (fr) 2010-04-27 2020-08-26 Roche Glycart AG Polythérapie d'un anticorps CD20 afucosylaté avec un inhibiteur mTOR
GB201012889D0 (en) 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
WO2011162343A1 (fr) 2010-06-25 2011-12-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 Agent anticancéreux utilisant des composés ayant un effet inhibiteur de kinase en combinaison
EP2593039B1 (fr) 2010-07-16 2022-11-30 Micell Technologies, Inc. Dispositif médical d'administration de médicament
US8889211B2 (en) 2010-09-02 2014-11-18 Boston Scientific Scimed, Inc. Coating process for drug delivery balloons using heat-induced rewrap memory
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
CN102464669B (zh) * 2010-11-17 2014-04-16 浙江海正药业股份有限公司 无定形依维莫司及其制备方法
WO2012066502A1 (fr) * 2010-11-19 2012-05-24 Biocon Limited Procédés de préparation d'évérolimus et d'intermédiaires de celui-ci
EP2670756B1 (fr) 2011-02-04 2017-06-21 Synthon BV Procédé pour la fabrication d'évérolimus
CA2827673C (fr) 2011-02-18 2020-10-27 Novartis Pharma Ag Pluritherapie impliquant un inhibiteur de mtor et un inhibiteur de jak
CN102174053B (zh) * 2011-03-09 2014-04-16 成都雅途生物技术有限公司 依维莫司的纯化方法
HUE065915T2 (hu) 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
EP2508525A1 (fr) 2011-04-05 2012-10-10 Bayer Pharma Aktiengesellschaft Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés
CN103402519B (zh) 2011-04-18 2015-11-25 卫材R&D管理有限公司 肿瘤治疗剂
PE20140601A1 (es) 2011-04-25 2014-05-24 Novartis Ag COMBINACION DE UN INHIBIDOR DE CINASA DE FOSFATIDIL-INOSITOL-3 (PI3K) Y UN INHIBIDOR DE mTOR
EP2702173A1 (fr) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Utilisation de signatures de gènes de tem dans la découverte de médicaments contre le cancer, diagnostics et traitement du cancer
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
JP2014516075A (ja) 2011-06-06 2014-07-07 シェブロン フィリップス ケミカル カンパニー エルピー 癌治療のためのメタロセン化合物の使用
EP2532740A1 (fr) 2011-06-11 2012-12-12 Michael Schmück Préparations de lymphocytes T à mémoire centrale CD4+ et CD8+ spécifiques aux antigènes pour thérapie de lymphocyte T adoptif
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
WO2013013708A1 (fr) 2011-07-26 2013-01-31 Fundació Institut D'investigació Biomèdica De Bellvitge Traitement du rejet aigu dans une transplantation rénale
US20130028895A1 (en) 2011-07-27 2013-01-31 Gerald Wulf Exosome inhibiting agents and uses thereof
WO2013022458A1 (fr) 2011-08-05 2013-02-14 Boston Scientific Scimed, Inc. Procédés de conversion d'une substance médicamenteuse amorphe en une forme cristalline
WO2013028208A1 (fr) 2011-08-25 2013-02-28 Boston Scientific Scimed, Inc. Dispositif médical comprenant un revêtement médicamenteux cristallin
CN102268015B (zh) * 2011-08-30 2013-08-28 成都摩尔生物医药有限公司 一种依维莫司的合成方法
GB201115665D0 (en) 2011-09-09 2011-10-26 Univ Leuven Kath Autoimmune and inflammatory disorder therapy
JP6368242B2 (ja) 2011-10-06 2018-08-01 ノバルティス アーゲー ４０−ｏ−（２−ヒドロキシ）エチル−ラパマイシンを含む医薬組成物
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
EP2589383A1 (fr) 2011-11-06 2013-05-08 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin Analogue de rapamycine spécifique au sous-type de FKBP à utiliser dans le traitement des maladies
GB201122305D0 (en) 2011-12-23 2012-02-01 Biotica Tech Ltd Novel compound
JP6301316B2 (ja) 2012-05-23 2018-03-28 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 内胚葉細胞および肝実質細胞の組成物ならびにそれらの細胞を入手および使用する方法
CN102786534A (zh) * 2012-05-25 2012-11-21 上海现代制药股份有限公司 一种依维莫司的制备方法
US9408884B2 (en) 2012-06-08 2016-08-09 Biotronik Ag Rapamycin 40-O-cyclic hydrocarbon esters, compositions and methods
WO2013192367A1 (fr) 2012-06-22 2013-12-27 Novartis Ag Traitement d'une tumeur neuroendocrine
CN103705925B (zh) 2012-09-29 2018-03-30 段磊 抑制PI3K/AKT/mTOR信号通路的药物组合
US9750728B2 (en) 2012-09-29 2017-09-05 Targeted Therapeutics, Llc Method and pharmaceutical composition for inhibiting PI3K/AKT/mTOR signaling pathway
US20150290176A1 (en) 2012-10-12 2015-10-15 The Board Of Regents Of The University Of Texas System Use of mtor inhibitors to treat vascular cognitive impairment
US20150258127A1 (en) 2012-10-31 2015-09-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing antiphospholipid syndrome (aps)
WO2014078522A1 (fr) 2012-11-14 2014-05-22 Ohio State Innovation Foundation Matières et procédés utiles pour le traitement du glioblastome
CA2863243A1 (fr) * 2012-11-30 2014-06-05 Hangzhou Zylox Pharma Co., Ltd. Analogue de la rapamycine et procedes de fabrication associes
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
WO2014110258A1 (fr) 2013-01-09 2014-07-17 Podack Eckhard R Compositions et procédés pour la régulation de lymphocytes t régulateurs à l'aide d'une protéine d'une fusion tl1a-ig
AU2014248508B2 (en) 2013-03-12 2018-11-08 Micell Technologies, Inc. Bioabsorbable biomedical implants
EP2968281B1 (fr) 2013-03-13 2020-08-05 The Board of Regents of The University of Texas System Inhibiteurs de mtor pour la prévention de la croissance de polypes intestinaux
KR20150127720A (ko) 2013-03-14 2015-11-17 유니버시티 오브 매릴랜드, 발티모어 안드로겐 수용체 하향 조절제 및 그의 용도
US10098871B2 (en) * 2013-03-15 2018-10-16 Leslie B. Gordon Combination therapies for treatment of laminopathies, cellular aging, and atherosclerosis
TW201503912A (zh) 2013-03-19 2015-02-01 Novartis Ag 包含癌莫事（ｅｖｅｒｏｌｉｍｕｓ）之醫藥組合物
EP2994758B1 (fr) 2013-05-08 2017-12-20 Opthea Limited Marqueurs biologiques de la dégénérescence maculaire liée à l'âge (dmla)
EP2997377B1 (fr) 2013-05-14 2018-07-18 Eisai R&D Management Co., Ltd. Biomarqueurs pour la prédiction et l'estimation de la sensibilité de sujets atteints d'un cancer de l' endometre vis-à-vis de composés lenvatinib
WO2014186532A1 (fr) 2013-05-15 2014-11-20 Micell Technologies, Inc. Implants biomedicaux bioabsorbables
US9593356B2 (en) 2013-06-11 2017-03-14 Takara Bio Usa, Inc. Protein enriched microvesicles and methods of making and using the same
EP3010926B1 (fr) * 2013-06-20 2019-11-20 Novartis AG Alkylation au moyen d'un fluoroalkylsulphonate d'alkyle
CN103360411B (zh) * 2013-07-17 2015-09-30 成都雅途生物技术有限公司 依维莫司结晶提纯方法
CA2920317A1 (fr) 2013-08-12 2015-02-19 Tokai Pharmaceuticals, Inc. Biomarqueurs pour le traitement de troubles neoplasiques a l'aide de therapies ciblant les androgenes
US9580758B2 (en) 2013-11-12 2017-02-28 Luc Montagnier System and method for the detection and treatment of infection by a microbial agent associated with HIV infection
CN105899232A (zh) 2013-11-13 2016-08-24 诺华股份有限公司 用于增强免疫应答的mTOR抑制剂
ES2918501T3 (es) 2013-12-19 2022-07-18 Novartis Ag Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
KR101529963B1 (ko) * 2013-12-27 2015-06-19 주식회사 종근당바이오 에베로리무스의 제조방법 및 이의 중간체
US9700544B2 (en) 2013-12-31 2017-07-11 Neal K Vail Oral rapamycin nanoparticle preparations
AU2014373683B2 (en) 2013-12-31 2020-05-07 Rapamycin Holdings, Llc Oral rapamycin nanoparticle preparations and use
WO2015108912A1 (fr) 2014-01-16 2015-07-23 MUSC Foundation for Research and Development Nanosupports ciblés pour l'administration d'agents immunosuppresseurs
RU2016135413A (ru) 2014-02-11 2018-03-14 Новартис Аг Фармацевтические комбинации, включающие ингибитор pi3k, для лечения рака
EP3593812A3 (fr) 2014-03-15 2020-05-27 Novartis AG Traitement du cancer à l'aide d'un récepteur d'antigène chimérique
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
CN103848849B (zh) * 2014-03-24 2016-02-24 上海医药工业研究院 依维莫司的制备工艺
CA2943609A1 (fr) 2014-03-27 2015-10-01 The Brigham And Women's Hospital, Inc. Conjugues de medicaments actives metaboliquement pour vaincre la resistance dans une therapie du cancer
AU2015244039B2 (en) 2014-04-07 2021-10-21 Novartis Ag Treatment of cancer using anti-CD19 chimeric antigen receptor
WO2015171723A1 (fr) 2014-05-06 2015-11-12 Research Development Foundation Méthodes pour traiter la résistance à l'insuline et pour sensibiliser des patients à un traitement avec un agoniste du glp1
CN105254646A (zh) * 2014-05-28 2016-01-20 上海博邦医药科技有限公司 一种制备依维莫司的方法
MX2016015569A (es) 2014-06-02 2017-04-25 Children´S Medical Center Corp Metodos y composiciones para inmunomodulacion.
SG10201913765YA (en) 2014-07-21 2020-03-30 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
WO2016014530A1 (fr) 2014-07-21 2016-01-28 Novartis Ag Combinaisons de faibles doses renforçant l'immunité d'inhibiteurs de mtor et car
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
TWI750110B (zh) 2014-07-21 2021-12-21 瑞士商諾華公司 使用人類化抗-ｂｃｍａ嵌合抗原受體治療癌症
ES2781175T3 (es) 2014-07-31 2020-08-31 Novartis Ag Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
WO2016020664A1 (fr) * 2014-08-04 2016-02-11 Cipla Limited Procédé de synthèse d'évérolimus et d'intermédiaires de ce dernier
EP4578865A3 (fr) 2014-08-12 2025-07-30 Monash University Promédicaments dirigeant la lymphe
CA2958200A1 (fr) 2014-08-14 2016-02-18 Novartis Ag Traitement du cancer a l'aide du recepteur d'antigene chimerique gfr alpha-4
ES2791248T3 (es) 2014-08-19 2020-11-03 Novartis Ag Receptor antigénico quimérico (CAR) anti-CD123 para su uso en el tratamiento del cáncer
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
WO2016040806A1 (fr) 2014-09-11 2016-03-17 The Regents Of The University Of California Inhibiteurs de mtorc1
KR20250067191A (ko) 2014-09-17 2025-05-14 노파르티스 아게 입양 면역요법을 위한 키메라 수용체에 의한 세포독성 세포의 표적화
KR20170068504A (ko) 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
CN107106588B (zh) 2014-10-28 2020-08-11 山口晃史 用于改善妊娠状态的药剂及其使用
WO2016066608A1 (fr) 2014-10-28 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour le traitement de la sénescence des cellules pulmonaires et le vieillissement périphérique
EP3212194A4 (fr) 2014-10-29 2018-06-20 University Of Maryland Procédés de traitement de symptômes liés à l'âge chez les mammifères et compositions à cet effet
CN104478898A (zh) * 2014-11-18 2015-04-01 连云港恒运医药科技有限公司 依维莫司及其中间体的制备方法
WO2016135740A1 (fr) 2015-02-23 2016-09-01 Natco Pharma Limited Procédé de préparation de compositions orales stables à base d'évérolimus
AU2016224583B2 (en) 2015-02-25 2021-06-03 Eisai R&D Management Co., Ltd. Method for suppressing bitterness of quinoline derivative
WO2016141092A1 (fr) 2015-03-04 2016-09-09 Gilead Sciences, Inc. Composés 4,6-diamino-pyrido[3,2-d]pyrimidine modulateurs du récepteur de type toll
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
SG11201708516YA (en) 2015-04-17 2017-11-29 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (fr) 2015-04-23 2018-02-28 Novartis AG Traitement du cancer à l'aide de protéine récepteur antigénique chimérique et un inhibiteur de protéine kinase
HK1245095A1 (zh) 2015-05-20 2018-08-24 Novartis Ag 依维莫司(everolimus)与达托里昔布(dactolisib)的医药组合
CN104892632B (zh) * 2015-06-03 2017-12-26 道中道（菏泽）制药有限公司 一种晶体形式的依维莫司及其制备方法
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
EP3109250A1 (fr) 2015-06-23 2016-12-28 Synbias Pharma AG Procede pour la synthese de derives de rapamycine
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
WO2017029391A1 (fr) 2015-08-20 2017-02-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Nouvelle méthode de traitement du cancer
WO2017040932A1 (fr) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Anticorps humanisés anti-cd40 et leurs utilisations
CA2997106C (fr) 2015-09-08 2024-06-04 Monash University Promedicaments ciblant la lymphe
IL258574B2 (en) 2015-11-11 2025-01-01 Novartis Ag Uses of myostatin antagonists, combinations containing them and their uses
CN105566348A (zh) * 2015-12-31 2016-05-11 哈药集团技术中心 一种依维莫司的制备方法
EP3442540A4 (fr) 2016-04-14 2019-12-18 Spinnaker Biosciences Inc. Matériaux de silicium poreux comprenant un silicate métallique pour l'administration d'agents thérapeutiques
EP4014967A1 (fr) * 2016-04-29 2022-06-22 Icahn School of Medicine at Mount Sinai Ciblage du système immunitaire inné pour induire une tolérance à long terme et pour résoudre l'accumulation de macrophages dans l'athérosclérose
JP6855470B2 (ja) 2016-05-27 2021-04-07 日本化薬株式会社 ラパマイシン又はその誘導体を含有する医薬組成物
EP3487878A4 (fr) 2016-07-20 2020-03-25 University of Utah Research Foundation Lymphocytes car-t cd229 et leurs procédés d'utilisation
CN109923106B (zh) 2016-09-02 2022-09-13 吉利德科学公司 toll样受体调节剂化合物
EP3507288B1 (fr) 2016-09-02 2020-08-26 Gilead Sciences, Inc. Dérivés de 4,6-diamino-pyrido[3,2-d]pyrimidine en tant que modulateurs du recepteur de type toll
EP3523331A1 (fr) 2016-10-07 2019-08-14 Novartis AG Récepteurs antigéniques chimériques pour le traitement du cancer
CN110114070A (zh) 2016-11-23 2019-08-09 诺华公司 使用依维莫司(everolimus)、达托里昔布(dactolisib)或二者增强免疫反应的方法
EP3548894B1 (fr) 2016-12-02 2021-10-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions permettant de diagnostiquer le carcinome cellulaire rénal
WO2018119183A2 (fr) 2016-12-22 2018-06-28 Amgen Inc. Inhibiteurs de kras g12c et leurs procédés d'utilisation
GB201701087D0 (en) 2017-01-23 2017-03-08 Univ Leuven Kath Novel prodrugs of mizoribine
JP6581320B2 (ja) 2017-02-08 2019-09-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療用医薬組成物
JP2020507632A (ja) * 2017-02-10 2020-03-12 マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. ラパマイシン類似体
WO2018201056A1 (fr) 2017-04-28 2018-11-01 Novartis Ag Cellules exprimant un récepteur antigénique chimérique ciblant le bcma, et polythérapie comprenant un inhibiteur de gamma sécrétase
EP3848065B1 (fr) 2017-05-15 2023-07-26 C. R. Bard, Inc. Dispositif médical à revêtement d'élution de médicament et à couche intermédiaire
EP3624800A4 (fr) 2017-05-16 2021-02-17 Eisai R&D Management Co., Ltd. Traitement du carcinome hépatocellulaire
EA201992781A1 (ru) 2017-05-22 2020-04-01 Эмджен Инк. Ингибиторы g12c kras и способы их применения
WO2019002168A1 (fr) 2017-06-26 2019-01-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Méthodes et compositions pharmaceutiques de traitement du syndrome d'olmsted
EP3652306A1 (fr) 2017-07-13 2020-05-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés pour augmenter la capacité immunosuppressive et d'expansion d'une population de cd8 + cd45rclow/-tregs
EP3675838A4 (fr) 2017-08-29 2021-04-21 PureTech LYT, Inc. Promédicaments lipidiques orientant vers le système lymphatique
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
MA50077A (fr) 2017-09-08 2020-07-15 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
AR112834A1 (es) 2017-09-26 2019-12-18 Novartis Ag Derivados de rapamicina
CN108047265A (zh) * 2017-11-24 2018-05-18 成都海创药业有限公司 一种依维莫司中间体的制备纯化方法
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
EP3784351A1 (fr) 2018-04-27 2021-03-03 Novartis AG Thérapies reposant sur des cellules car-t présentant une efficacité améliorée
US20210396739A1 (en) 2018-05-01 2021-12-23 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
IL300091A (en) 2018-05-01 2023-03-01 Revolution Medicines Inc C40-, c28-, and c-32-linked rapamycin analogs as mtor inhibitors
CN112368289B (zh) 2018-05-01 2024-02-20 锐新医药公司 作为mtor抑制剂的c26-连接的雷帕霉素类似物
ES2995514T3 (en) 2018-05-04 2025-02-10 Amgen Inc Kras g12c inhibitors and methods of using the same
WO2019213516A1 (fr) 2018-05-04 2019-11-07 Amgen Inc. Inhibiteurs de kras g12c et leurs procédés d'utilisation
EP3790886B1 (fr) 2018-05-10 2024-06-26 Amgen Inc. Inhibiteurs du kras g12c pour le traitement du cancer
EP3796948A4 (fr) 2018-05-22 2022-03-02 Interface Biologics Inc. Compositions et procédés d'administration de médicaments à une paroi de vaisseau
AR126019A1 (es) 2018-05-30 2023-09-06 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
ES2938987T3 (es) 2018-06-01 2023-04-18 Amgen Inc Inhibidores de KRAS G12c y métodos de uso de los mismos
US20190375749A1 (en) 2018-06-11 2019-12-12 Amgen Inc. Kras g12c inhibitors and methods of using the same
ES3060664T3 (en) 2018-06-12 2026-03-27 Amgen Inc Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
CA3100724A1 (fr) 2018-06-13 2019-12-19 Novartis Ag Recepteurs antigenes chimeres de la proteine de l'antigene de maturation des lymphocytes b (bcma) et utilisations connexes
CN108676014A (zh) * 2018-06-15 2018-10-19 国药集团川抗制药有限公司 纯化依维莫司中间体的方法以及制备依维莫司的方法
JP2022510573A (ja) 2018-07-23 2022-01-27 エンクリアー セラピーズ， インク． 神経障害の治療方法
CN113164557A (zh) 2018-07-23 2021-07-23 因柯利尔疗法公司 治疗神经性病症的方法
WO2020053125A1 (fr) 2018-09-10 2020-03-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés de traitement de la neurofibromatose
US20210349097A1 (en) 2018-10-05 2021-11-11 Eisai R&D Management Co., Ltd. Biomarkers for a combination therapy comprising lenvatinib and everolimus
EP3880266B1 (fr) 2018-11-14 2025-05-07 Lutonix, Inc. Dispositif médical avec revêtement à élution de médicament sur un dispositif à surface modifiée
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
US11053226B2 (en) 2018-11-19 2021-07-06 Amgen Inc. KRAS G12C inhibitors and methods of using the same
MX2021007247A (es) 2018-12-18 2021-07-15 Novartis Ag Derivados de rapamicina.
EP3898616B1 (fr) 2018-12-20 2024-10-02 Amgen Inc. Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
WO2020132651A1 (fr) 2018-12-20 2020-06-25 Amgen Inc. Inhibiteurs de kif18a
JP7676308B2 (ja) 2018-12-20 2025-05-14 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
TWI844602B (zh) 2018-12-20 2024-06-11 美商安進公司 Kif18a抑制劑
JPWO2020130125A1 (ja) 2018-12-21 2021-11-04 第一三共株式会社 抗体−薬物コンジュゲートとキナーゼ阻害剤の組み合わせ
EP3914245A4 (fr) * 2019-01-22 2022-08-24 Aeovian Pharmaceuticals, Inc. Modulateurs de mtorc et leurs utilisations
WO2020163594A1 (fr) 2019-02-07 2020-08-13 The Regents Of The University Of California Agents de liaison à l'immunophiline et leurs utilisations
CN113727758A (zh) 2019-03-01 2021-11-30 锐新医药公司 双环杂环基化合物及其用途
WO2020180768A1 (fr) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Composés hétéroaryle bicycliques et leurs utilisations
WO2020209828A1 (fr) 2019-04-08 2020-10-15 Bard Peripheral Vascular, Inc. Dispositif médical portant un revêtement d'élution de médicament sur une surface modifiée de dispositif
JP2022526671A (ja) 2019-04-11 2022-05-25 エンクリアー セラピーズ， インク． 脳脊髄液の改善の方法ならびにそのためのデバイスおよびシステム
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
EP3738593A1 (fr) 2019-05-14 2020-11-18 Amgen, Inc Dosage d'inhibiteur de kras pour le traitement de cancers
NZ782284A (en) 2019-05-21 2024-11-29 Amgen Inc Solid state forms
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
TW202114681A (zh) 2019-07-02 2021-04-16 美商ｅＦＦＥＣＴＯＲ醫療公司 轉譯抑制劑及其用途
US12540129B2 (en) 2019-08-02 2026-02-03 Amgen Inc. KIF18A inhibitors
AU2020326627B2 (en) 2019-08-02 2026-01-29 Amgen Inc. KIF18A inhibitors
WO2021026099A1 (fr) 2019-08-02 2021-02-11 Amgen Inc. Inhibiteurs de kif18a
EP4007756B1 (fr) 2019-08-02 2025-12-24 Amgen Inc. Inhibiteurs de kif18a
IL320609A (en) 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
US20220348651A1 (en) 2019-09-18 2022-11-03 Novartis Ag Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
EP4031542B1 (fr) 2019-09-18 2025-10-15 Merck Sharp & Dohme LLC Petites molécules inhibitrices de mutant de kras g12c
EP4684786A3 (fr) 2019-10-24 2026-04-08 Amgen Inc. Dérivés de pyridopyrimidine utiles en tant qu'inhibiteurs de kras g12c et de kras g12d dans le traitement du cancer
CN114867726B (zh) 2019-10-28 2023-11-28 默沙东有限责任公司 Kras g12c突变体的小分子抑制剂
WO2021085653A1 (fr) 2019-10-31 2021-05-06 Taiho Pharmaceutical Co., Ltd. Dérivés de 4-aminobut-2-enamide et sels de ces derniers
MX2022005359A (es) 2019-11-04 2022-06-02 Revolution Medicines Inc Inhibidores de ras.
WO2021091956A1 (fr) 2019-11-04 2021-05-14 Revolution Medicines, Inc. Inhibiteurs de ras
CN120699039A (zh) 2019-11-04 2025-09-26 锐新医药公司 Ras抑制剂
TW202128688A (zh) 2019-11-08 2021-08-01 美商銳新醫藥公司 雙環雜芳基化合物及其用途
JP2023501528A (ja) 2019-11-14 2023-01-18 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の改善された合成
WO2021097207A1 (fr) 2019-11-14 2021-05-20 Amgen Inc. Synthèse améliorée de composés inhibiteurs de kras g12c
EP4065231A1 (fr) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Inhibiteurs de ras covalents et leurs utilisations
WO2021106231A1 (fr) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. Composé ayant une activité inhibitrice contre la mutation kras g12d
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
CN114929279A (zh) 2020-01-07 2022-08-19 锐新医药公司 Shp2抑制剂给药和治疗癌症的方法
CN115348864A (zh) 2020-02-05 2022-11-15 纯技术Lyt股份有限公司 神经甾体的脂质前药
WO2021215545A1 (fr) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Polythérapie anticancéreuse avec un inhibiteur de n-(1-acryloyl-azétidin-3-yl)-2-((1h-indazol-3-yl) amino) méthyl)-1 h-imidazole-5-carboxamide de kras-g12c
WO2021215544A1 (fr) 2020-04-24 2021-10-28 Taiho Pharmaceutical Co., Ltd. Inhibiteurs de protéine kras g12d
EP4183395A4 (fr) 2020-07-15 2024-07-24 Taiho Pharmaceutical Co., Ltd. Combinaison contenant un composé pyrimidine destinée à être utilisée dans le traitement de tumeurs
MX2023002248A (es) 2020-09-03 2023-05-16 Revolution Medicines Inc Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2.
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
JP2023543868A (ja) 2020-09-29 2023-10-18 エンクリアー セラピーズ， インク． くも膜下液管理方法およびシステム
US20240051956A1 (en) 2020-12-22 2024-02-15 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
CN118459539B (zh) 2021-03-19 2026-01-06 生物治疗探索股份有限公司 用于调节训练免疫的化合物及其使用方法
AU2022268962A1 (en) 2021-05-05 2023-12-14 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
WO2022235866A1 (fr) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Inhibiteurs de ras covalents et leurs utilisations
CA3217393A1 (fr) 2021-05-05 2022-11-10 Elena S. Koltun Inhibiteurs de ras
WO2022250170A1 (fr) 2021-05-28 2022-12-01 Taiho Pharmaceutical Co., Ltd. Petites molécules inhibitrices de protéines mutées par kras
CA3223081A1 (fr) 2021-07-15 2023-01-19 Samir Mitragotri Compositions et methodes associees a des cellules comprenant des particules adherees
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023064058A1 (fr) 2021-10-12 2023-04-20 Peloton Therapeutics Inc. Sultames et sulfamides tricycliques utilisés en tant qu'agents antitumoraux
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
EP4227307A1 (fr) 2022-02-11 2023-08-16 Genzyme Corporation Composés pyrazolopyrazine en tant qu'inhibiteurs de shp2
WO2023172858A1 (fr) 2022-03-07 2023-09-14 Amgen Inc. Procédé de préparation de 4-méthyl-2-propan-2-yl-pyridine-3-carbonitrile
CN119136806A (zh) 2022-03-08 2024-12-13 锐新医药公司 用于治疗免疫难治性肺癌的方法
AU2023275778A1 (en) 2022-05-25 2024-12-12 Revolution Medicines, Inc. Methods of treating cancer with an mtor inhibitor
WO2023240263A1 (fr) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Inhibiteurs de ras macrocycliques
JP2025521677A (ja) 2022-07-06 2025-07-10 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 増殖性糸球体腎炎を処置するための方法
US20260060969A1 (en) 2022-08-04 2026-03-05 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of lymphoproliferative disorders
AU2023358792A1 (en) 2022-10-14 2025-04-17 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
EP4615431A1 (fr) 2022-11-11 2025-09-17 Astrazeneca AB Polythérapies pour le traitement du cancer
WO2024167904A1 (fr) 2023-02-07 2024-08-15 Arvinas Operations, Inc. Régimes posologiques d'agents de dégradation des récepteurs des œstrogènes en association avec un inhibiteur de mtor
EP4687905A1 (fr) 2023-03-30 2026-02-11 Revolution Medicines, Inc. Compositions pour induire une hydrolyse de ras gtp et leurs utilisations
KR20260005904A (ko) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. 매크로사이클릭 ras 억제제
CN121263418A (zh) 2023-04-07 2026-01-02 锐新医药公司 大环ras抑制剂
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
CN116813641A (zh) * 2023-06-09 2023-09-29 杭州华东医药集团康润制药有限公司 一种依维莫司的制备方法
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
KR20260042550A (ko) 2023-08-24 2026-03-31 다이호야쿠힌고교 가부시키가이샤 세다주리딘 및 아자시티딘의 고정 용량 조합물
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025085748A1 (fr) 2023-10-20 2025-04-24 Merck Sharp & Dohme Llc Inhibiteurs à petites molécules de protéines kras
TW202542151A (zh) 2023-12-22 2025-11-01 美商銳格醫藥有限公司 Ｓｏｓ１抑制劑及其用途
WO2025171296A1 (fr) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Inhibiteurs de ras
WO2025240847A1 (fr) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Inhibiteurs de ras
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (fr) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Compositions thérapeutiques et procédés de gestion d'effets liés au traitement
WO2026006747A1 (fr) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026015825A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Utilisation d'un inhibiteur de ras pour traiter le cancer du pancréas
WO2026015790A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026015801A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble liés à ras
WO2026015796A1 (fr) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Méthodes de traitement d'une maladie ou d'un trouble lié à ras
WO2026050446A1 (fr) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Inhibiteurs de ras
WO2026072904A2 (fr) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions et méthodes de traitement du cancer du poumon

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308166D0 (en) * 1983-03-24 1983-05-05 Erba Farmitalia Preparation of azinomethyl-rifamycins
EP0429436A3 (en) * 1985-12-06 1991-12-27 The University Of Kansas Prodrugs of rapamycin
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin
US5120842A (en) * 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
US5151413A (en) * 1991-11-06 1992-09-29 American Home Products Corporation Rapamycin acetals as immunosuppressant and antifungal agents
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
US5310903A (en) * 1993-03-05 1994-05-10 Merck & Co., Inc. Imidazolidyl rapamycin derivatives
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
US5912253A (en) * 1993-12-17 1999-06-15 Novartis Ag Rapamycin derivatives

Also Published As

Publication number Publication date
NO2017067I1 (no) 2017-12-07
FR04C0012I1 (fr) 2004-09-17
HU9501016D0 (en) 1995-06-28
EP1413581A1 (fr) 2004-04-28
NL300154I2 (nl) 2004-10-01
DE69333577T2 (de) 2005-07-21
BR1100353A (pt) 2000-06-06
US5665772A (en) 1997-09-09
GB9221220D0 (en) 1992-11-25
DE122004000033I2 (de) 2006-12-21
CY2125B1 (en) 2002-06-21
GEP20002331B (en) 2000-12-25
FR04C0012I2 (fr) 2005-02-11
DE69322282D1 (de) 1999-01-07
FI951678A0 (fi) 1995-04-07
DK0663916T3 (da) 1999-08-09
JPH08502266A (ja) 1996-03-12
JP3117462B2 (ja) 2000-12-11
AU4819293A (en) 1994-05-09
NO951312L (no) 1995-06-08
RU2143434C1 (ru) 1999-12-27
ES2225919T3 (es) 2005-03-16
FI951678L (fi) 1995-04-07
NZ256026A (en) 1996-08-27
CA2145383A1 (fr) 1994-04-28
CZ283333B6 (cs) 1998-02-18
ATE272063T1 (de) 2004-08-15
NO307053B1 (no) 2000-01-31
HU224074B1 (hu) 2005-05-30
NO2017067I2 (no) 2017-12-07
SK286054B6 (sk) 2008-02-05
ES2124793T3 (es) 1999-02-16
RU95110053A (ru) 1997-03-20
DE69333577D1 (de) 2004-09-02
CY2005010I2 (el) 2016-10-05
RO114451B1 (ro) 1999-04-30
KR100308598B1 (ko) 2001-11-30
NL300154I1 (nl) 2004-09-01
JP3568800B2 (ja) 2004-09-22
CA2476257A1 (fr) 1994-04-28
EP0663916A1 (fr) 1995-07-26
DE69322282T2 (de) 1999-05-12
CA2476257C (fr) 2009-11-10
SK285256B6 (sk) 2006-10-05
NO951312D0 (no) 1995-04-05
KR100307831B1 (ko) 2001-09-24
CZ89995A3 (en) 1995-09-13
AU676198B2 (en) 1997-03-06
FI20001943L (fi) 2000-09-04
HUT71232A (en) 1995-11-28
KR950703567A (ko) 1995-09-20
SK46595A3 (en) 1995-08-09
PL176174B1 (pl) 1999-04-30
DE122004000033I1 (de) 2006-11-16
DK0867438T3 (da) 2004-12-06
US6440990B1 (en) 2002-08-27
JPH11240884A (ja) 1999-09-07
FI109540B (fi) 2002-08-30
EP0867438B1 (fr) 2004-07-28
ATE173736T1 (de) 1998-12-15
WO1994009010A1 (fr) 1994-04-28
FI20001943A7 (fi) 2000-09-04
PT867438E (pt) 2004-11-30
EP0867438A1 (fr) 1998-09-30
CY2005010I1 (el) 2010-07-28
EP0663916B1 (fr) 1998-11-25
CA2145383C (fr) 2004-11-16
NO2004001I2 (no) 2006-04-10
PL308268A1 (en) 1995-07-24

Similar Documents

Publication Publication Date Title
LU91104I2 (fr) Derive o-alkyle de la rapamycine et son utilisation, en pariculier comme immunosuppresseur.
NZ502181A (en) Triazole compounds and the use thereof as dopamine-D 3-ligands
HUT45371A (en) Process for production of derivatives of 3-phenil-4-zyan pirrole and microbicides containing these compounds as active substance
AU7579094A (en) Methods for the treatment of peri-menopausal syndrome
NZ332658A (en) Halo-substituted bis-indolylmaleimide derivatives and pharmaceutical compositions
MX9708696A (es) Cefalosporinas antibacterianas.
CA2149496A1 (fr) Derives du 11,21-bisphenyl-19-norpregnane
TW354762B (en) Agent for prophylaxis or treatment of cataract
NO994659L (no) Nye pyridinderivater og farmasöytiske preparater inneholdende slike
DE69132580D1 (de) 7-Acyl-3-(substituierte carbamoyloxy) Cephem Verbindungen, Verfahren zu ihrer Herstellung und Anwendung
HUT58097A (en) Process for producing 3,7-diazobicyclo(3,3.1)nonane compounds and pharmaceutical compositions comprising same
DE69031730D1 (de) Neues Antibiotikum, Deoxymulündocandin, Verfahren zu seiner Produktion und Verwendung als Medikament
DE3779738D1 (de) Amycin und dessen derivate, verfahren zu deren herstellung und deren verwendung.
MX9804955A (es) Antibioticos hidrosolubles.
MX9604072A (es) Derivados de oxazolidinona y composiciones farmaceuticas que los contienen.
EP0652220A4 (fr) Derive de cephalosporine.